Healthy Young AdultsNCT07821515
Does Paracetamol Influence the Release of Gut Hormones, Glucose Absorption and Glycemia?
A study testing Paracetamol in people with Healthy Young Adults and Physiology, run by University of Copenhagen at 2 sites in Denmark.
Trial summary
The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Healthy Young Adults, Physiology
- What is being tested?
- Paracetamol
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 12 participants
- Where
- 2 sitesDenmark
- Study dates
- 1 Jun 2026to 31 Dec 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥ 18 years
- Nondiabetic fasting plasma glucose (< 7.0 mmol/L) at time of inclusion
- BMI of 20-25
- Written informed consent
Who cannot join
- Haemoglobin < 7.9 mmol/L
- Pregnancy or breastfeeding
- Significant gastrointestinal symptoms (e.g. dyspepsia, postprandial pain)
- Use of medication that cannot be paused for 12 hours or any drug that affects gastric emptying, small intestinal motility, glucose absorption.
- Use of paracetamol, NSAID, aspirin or similar within the previous week.
- Evidence of drug abuse, consumption of tobacco in any form or daily consumption of more than 20g alcohol
Show all 10Show fewer
- History of gastrointestinal disease, including significant upper or lower gastrointestinal symptoms, pancreatitis, or previous gastrointestinal surgery including cholecystectomy (but not uncomplicated appendicectomy)
- Participation in other research studies within the previous 3 months
- Inability to give informed consent
- Intolerance to any of the components of paracetamol and the meals used for the study
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark2 sites, 2 recruiting
- Recruiting
Department of Biomedical Sciences, The Panum Institute, University of Copenhagen,
Copenhagen, Capital, 2200
Simon Veedfald, MD, PhD., +45 41102595, veedfald@sund.ku.dk
Jonatan Friis, MD, jonatan.sverri.kure.friis@sund.ku.dk
- Recruiting
Hvidovre Hospital, Copenhagen University Hospital
Hvidovre, 2650
Jonatan Friis, MD, Jonatan.sverri.kure.friis@regionh.dk
About this study
The study aim is to determine whether acute inhibition of endogenous prostaglandin synthesis by paracetamol affects the release of gut hormones, glucose absorption and glycemia in healthy young individuals
- Conditions
- Healthy Young Adults, Physiology
- Being tested
- Paracetamol, Placebo
- Keywords
- prostaglandins, glucose, gut hormones, Paracetamol, GLP-1, GIP, meal test
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ParacetamolOther
Paracetamol is used as a tool to block prostaglandin synthesis
PlaceboOther
A placebo will be administered to be able to determine the effect of paracetamol on prostaglandin synthesis
| Study group | Role | What they receive |
|---|---|---|
| Paracetamol (1000mg) | Active comparator | Not described Receives: Other: Paracetamol |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucagon-like peptide 1
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Secondary outcomes (8)
Glucose
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Gastrin
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Cholecystokinin
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Glucose-dependent insulinotropic polypeptide (GIP)
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
C-peptide
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Glucagon
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Pancreatic polypeptide
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
3-OMG
Plasma concentration
Measured: From baseline samples (-15, 0 min) until the end of the meal test at t = 180min
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Sep 2026
- Study start1 Jun 2026
- Primary completion30 Sep 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Young AdultsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Randomised double blind placebo-controlled trial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- Hvidovre University Hospital
- Responsible party
- Principal investigator, Simon Veedfald, University of Copenhagen
- Investigators
- Simon Veedfald, MD, PhD, Principal investigator, Department of BIomedical Scienes, University Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07821515
- Sponsor's protocol ID
- PCT-2026
- Status last verified
- Sep 2026
- First submitted
- 9 Sep 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No